Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manon Allaire

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 22, 2018
Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosisManon Allaire, Samia Rekik, Richard Layese, et al.
Hepatology (Baltimore, Md.)|October 23, 2023
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumabClaudia Campani, Ariane Vallot, Haroun Ghannouchi, et al.
The Lancet Regional Health. Europe|August 13, 2025
Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer AssociationManon Allaire, Leonardo G Da Fonseca, Marco Sanduzzi-Zamparelli, et al.
Annals of Hepatology|September 14, 2025
Prognosis of hepatocellular carcinoma in the French overseas territories and comparison with a tertiary center in mainland FranceAlolia Aboikoni, Manon Allaire, Dominique Louvel, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 29, 2022
Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumabClaudia Campani, Jessica Bamba-Funck, Bertille Campion, et al.
Journal of Hepatology|March 9, 2018
Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinomaJulia Chalaye, Charlotte E Costentin, Alain Luciani, et al.
JHEP Reports : Innovation in Hepatology|July 31, 2023
Monoacylglycerol lipase reprograms hepatocytes and macrophages to promote liver regenerationManon Allaire, Rola Al Sayegh, Morgane Mabire, et al.
Nature Communications|April 3, 2023
MAIT cell inhibition promotes liver fibrosis regression via macrophage phenotype reprogrammingMorgane Mabire, Pushpa Hegde, Adel Hammoutene, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 21, 2023
Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trialPhilippe Merle, Jean-Frédéric Blanc, Julien Edeline, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2026
Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumabErwan Vo-Quang, Claudia Campani, Manon Allaire, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 22, 2018
Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosisManon Allaire, Samia Rekik, Richard Layese, et al.
Hepatology (Baltimore, Md.)|October 23, 2023
Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumabClaudia Campani, Ariane Vallot, Haroun Ghannouchi, et al.
The Lancet Regional Health. Europe|August 13, 2025
Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer AssociationManon Allaire, Leonardo G Da Fonseca, Marco Sanduzzi-Zamparelli, et al.
Annals of Hepatology|September 14, 2025
Prognosis of hepatocellular carcinoma in the French overseas territories and comparison with a tertiary center in mainland FranceAlolia Aboikoni, Manon Allaire, Dominique Louvel, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 29, 2022
Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumabClaudia Campani, Jessica Bamba-Funck, Bertille Campion, et al.
Journal of Hepatology|March 9, 2018
Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinomaJulia Chalaye, Charlotte E Costentin, Alain Luciani, et al.
JHEP Reports : Innovation in Hepatology|July 31, 2023
Monoacylglycerol lipase reprograms hepatocytes and macrophages to promote liver regenerationManon Allaire, Rola Al Sayegh, Morgane Mabire, et al.
Nature Communications|April 3, 2023
MAIT cell inhibition promotes liver fibrosis regression via macrophage phenotype reprogrammingMorgane Mabire, Pushpa Hegde, Adel Hammoutene, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 21, 2023
Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trialPhilippe Merle, Jean-Frédéric Blanc, Julien Edeline, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2026
Clinical impact of extrahepatic metastatic patterns in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumabErwan Vo-Quang, Claudia Campani, Manon Allaire, et al.
Pageof 9